Science and Research

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4- Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

Effect of NAL ER on 24-hour
cough frequency (coughs per
hour) at Week 6 using objective
digital cough monitoring.

Study details
Study-ID: 2023-505296-72-00
Study-ID: 2023-505296-72-00
DZL Disease Area: DPLD
DZL Disease Area: DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 17.05.2024
Completion Date: 28.02.2025
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.